Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.89+0.02 (+0.52%)
Close on Nov 18, 2026Market cap $161.81MP/E 0.9Yield 6.43%
Oramed Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Oramed Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$14.52M. For fiscal 2025 it was -$15.09M. The highest annual figure on record is $4.30M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.09M | – |
| FY2024 | Dec 31, 2024 | -$12.78M | – |
| FY2023 | Dec 31, 2023 | -$15.77M | – |
| FY2021 | Aug 31, 2021 | -$24.22M | – |
| FY2020 | Aug 31, 2020 | -$11.76M | – |
| FY2019 | Aug 31, 2019 | -$14.63M | – |
| FY2018 | Aug 31, 2018 | -$13.53M | – |
| FY2017 | Aug 31, 2017 | -$10.77M | – |
| FY2016 | Aug 31, 2016 | -$10.01M | – |
| FY2015 | Aug 31, 2015 | -$7.38M | – |
| FY2014 | Aug 31, 2014 | -$5.91M | -237.2% |
| FY2013 | Aug 31, 2013 | $4.30M | – |
| FY2012 | Aug 31, 2012 | -$2.88M | – |
| FY2011 | Aug 31, 2011 | -$2.44M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$2.77M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$3.66M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$5.67M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$2.43M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$2.49M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$4.50M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$3.60M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$3.09M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$3.14M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.96M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$3.88M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$2.89M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$3.79M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$5.21M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$7.41M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$6.12M | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$4.87M | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$5.83M | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$3.02M | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$2.27M | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$4.04M | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$2.43M | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$2.35M | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$4.08M | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$3.15M | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$4.53M | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$3.11M | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$2.73M | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$2.85M | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$2.16M | -202.1% |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$3.37M | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$2.40M | -197.9% |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$16.48M | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | $2.11M | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | -$1.91M | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $2.45M | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | -$2.17M | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$1.63M | – |
| Q2 FY2015CQ1 2015 | Feb 28, 2015 | -$1.67M | – |
See a number that looks wrong?